Barely Significant
← all excerpts

Prim-O-glucosylcimifugin ameliorates DSS-induced ulcerative colitis via suppressing NLRP3 inflammasome activation.

Front Pharmacol · 2026 · PMC13043649 · PMID 41939840

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

showed a trendP < 0.05actually significant
However, on day 10, POG-H showed a trend toward preventing weight loss, with POG-L having a significant but transient effect on a single day ( P < 0.05).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.